IS5283A - Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín - Google Patents

Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín

Info

Publication number
IS5283A
IS5283A IS5283A IS5283A IS5283A IS 5283 A IS5283 A IS 5283A IS 5283 A IS5283 A IS 5283A IS 5283 A IS5283 A IS 5283A IS 5283 A IS5283 A IS 5283A
Authority
IS
Iceland
Prior art keywords
caffeine
pharmaceutical formulations
pct
formulations containing
eletriptan hemisulfate
Prior art date
Application number
IS5283A
Other languages
English (en)
Inventor
Denise Harding Valerie
Billotte Anne
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5283A publication Critical patent/IS5283A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5283A 1997-07-03 1999-11-30 Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín IS5283A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (1)

Publication Number Publication Date
IS5283A true IS5283A (is) 1999-11-30

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5283A IS5283A (is) 1997-07-03 1999-11-30 Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín

Country Status (30)

Country Link
US (1) US6166025A (is)
EP (1) EP0999841B1 (is)
JP (1) JP3350061B2 (is)
CN (1) CN1145486C (is)
AT (1) ATE206921T1 (is)
AU (1) AU724728B2 (is)
BG (1) BG103930A (is)
BR (1) BR9810658A (is)
CA (1) CA2292673C (is)
DE (1) DE69802097T2 (is)
DK (1) DK0999841T3 (is)
DZ (1) DZ2549A1 (is)
EA (1) EA002174B1 (is)
ES (1) ES2163291T3 (is)
HR (1) HRP990416B1 (is)
HU (1) HUP0004468A3 (is)
ID (1) ID24528A (is)
IL (1) IL133206A0 (is)
IS (1) IS5283A (is)
MA (1) MA26518A1 (is)
NO (1) NO312993B1 (is)
NZ (1) NZ501419A (is)
OA (1) OA11227A (is)
PL (1) PL337803A1 (is)
PT (1) PT999841E (is)
SI (1) SI0999841T1 (is)
SK (1) SK284462B6 (is)
TR (1) TR199903332T2 (is)
UY (1) UY25078A1 (is)
WO (1) WO1999001135A1 (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU4799700A (en) 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20080286388A1 (en) * 2004-10-22 2008-11-20 Shin-Jen Shiao Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2009504767A (ja) 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンb12鼻用スプレーおよび使用方法
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤
US8915245B2 (en) * 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
EP2968204B1 (en) * 2013-03-15 2019-05-15 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
CN109248365B (zh) 2013-08-08 2021-11-12 蒸汽热能公司 呼吸治疗凝结物适配器
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル, インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス, インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
AU2024274892A1 (en) * 2023-05-24 2025-12-11 Defuse Technologies, LLC Desensitized fertilizer compositions and methods of making same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
CA2292673C (en) 2003-04-22
ID24528A (id) 2000-07-20
BR9810658A (pt) 2000-10-03
PT999841E (pt) 2002-02-28
IL133206A0 (en) 2001-03-19
DE69802097T2 (de) 2002-03-14
DE69802097D1 (de) 2001-11-22
WO1999001135A1 (en) 1999-01-14
BG103930A (en) 2000-07-31
CN1261279A (zh) 2000-07-26
CA2292673A1 (en) 1999-01-14
HUP0004468A3 (en) 2004-07-28
HRP990416B1 (en) 2002-04-30
HUP0004468A2 (hu) 2001-10-28
EA002174B1 (ru) 2002-02-28
HRP990416A2 (en) 2000-04-30
NO312993B1 (no) 2002-07-29
AU724728B2 (en) 2000-09-28
NO995887L (no) 2000-03-02
TR199903332T2 (xx) 2000-09-21
OA11227A (en) 2003-07-18
AU8856998A (en) 1999-01-25
UY25078A1 (es) 2000-12-29
DZ2549A1 (fr) 2003-02-08
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
CN1145486C (zh) 2004-04-14
SK182899A3 (en) 2000-09-12
EA199901100A1 (ru) 2000-08-28
EP0999841A1 (en) 2000-05-17
US6166025A (en) 2000-12-26
JP3350061B2 (ja) 2002-11-25
NZ501419A (en) 2000-09-29
ES2163291T3 (es) 2002-01-16
EP0999841B1 (en) 2001-10-17
ATE206921T1 (de) 2001-11-15
SI0999841T1 (is) 2001-12-31
JP2000516262A (ja) 2000-12-05
DK0999841T3 (da) 2001-11-19
PL337803A1 (en) 2000-09-11
SK284462B6 (sk) 2005-04-01
HK1029282A1 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
IS5283A (is) Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín
MX9707431A (es) Inhibidores de la proteina cinasa c.
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
MY118068A (en) Protein kinase c inhibitor
ATE219765T1 (de) Indolderivate als cgmp-pde inhibitoren
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
ATE310738T1 (de) Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
BG106155A (en) Novel derivatives and analogues of galanthamin
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
IL141236A0 (en) New oral formulations for 5-ht4 agonists or antagonists
IL132853A0 (en) Combination therapy for modulating the human sexual response
ZA200303113B (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them.
UY27373A1 (es) Formulaciones de interferón beta-humano
PT917460E (pt) Formulacoes de ciclosporina
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
AP2001002369A0 (en) Pharmaceutical complex.
IL102058A0 (en) Pharmaceutical compositions containing a nucleoside derivative